Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/158997
Title: | Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis |
Author: | Sosa Díaz, Lilian Elisa Calpena Campmany, Ana Cristina Silva Abreu, Marcelle Espinoza, Lupe Carolina Rincón, María Bozal de Febrer, Núria Domènech Cabrera, Òscar Rodríguez Lagunas, María José Clares Naveros, Beatriz |
Keywords: | Candidiasi Copolímers Gels (Farmàcia) Candidiasis Copolymers Gels (Pharmacy) |
Issue Date: | 3-Jul-2019 |
Publisher: | MDPI |
Abstract: | The present study was designed to develop a thermoreversible gel of Pluronic (P407) loaded amphotericin B (AmB-gel) for the dermal and vaginal treatment of candidiasis. P407 was used as a copolymer to exploit potential advantages related to increasing drug concentration in the tissue layer in order to provide a local effect. Parameters including internal structure, swelling, porosity, and short-term stability were determined. In addition, drug release profile and ex vivo skin and vaginal permeation studies were carried out. Antifungal efficacy was evaluated against strains of Candida spp. and atomic force microscopy (AFM) supported the results. The tolerance of AmB-gel was studied by evaluating biomechanical properties of skin and determining the irritation level in scarified rabbit skin supported by histological analysis. Results confirmed the development of a thermoreversible AmB-gel with high porosity exhibiting Newtonian behavior at 4 °C and pseudoplasticity at 32 °C as well as optimal stability for at least 90 days. The Amb-gel provided a sustained drug release following a Boltzmann sigmoidal model. Non permeation was observed in skin and vaginal mucosa, showing a high retained amount of AmB of 960.0 and 737.3 µg/g/cm2, respectively. In vitro antifungal efficacy showed that AmB-gel was more effective than Free-AmB in inhibiting strains of Candida spp. and these results were corroborated by AFM. Finally, tolerance studies showed that its application did not induce skin irritation nor alter its biophysical properties. Together, these results confirmed that AmB-gel could be proposed as a promising candidate for the clinical status in the treatment of skin and vaginal candidiasis. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11070312 |
It is part of: | Pharmaceutics, 2019, vol. 11, num. 7, p. 312 |
URI: | https://hdl.handle.net/2445/158997 |
Related resource: | https://doi.org/10.3390/pharmaceutics11070312 |
ISSN: | 1999-4923 |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) Articles publicats en revistes (Bioquímica i Fisiologia) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
691101.pdf | 5.17 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License